Arrowstreet Capital’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Arrowstreet Capital’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-223,990	Closed	-$2.15M	–	2074
2024 Q4	$2.15M	Sell	223,990 -127,376	-36%	-$665K	﹤0.01%	1254
2024 Q3	$1M	Buy	+351,366	New	+$1.09M	﹤0.01%	1385
2023 Q3	–	Sell	-99,598	Closed	-$175K	–	1460
2023 Q2	$175K	Buy	+99,598	New	+$254K	﹤0.01%	1172
2023 Q1	–	Sell	-15,975	Closed	-$85K	–	1572
2022 Q4	$85K	Hold	15,975	–	–	﹤0.01%	1295
2022 Q3	$56K	Buy	+15,975	New	+$52.8K	﹤0.01%	1238

Other funds holding PSTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Arrowstreet Capital's PSTX Position: Q1 2025 in Review

Arrowstreet Capital sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 223,990 shares — an estimated $2.15M sold.

Arrowstreet Capital first reported a position in PSTX in Q3 2022 and held it in 5 quarters. The position peaked at $2.15M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

Arrowstreet Capital reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Arrowstreet Capital sold 223,990 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $2.15M.
Arrowstreet Capital first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2022 and held it in 5 quarters.
Arrowstreet Capital's Poseida Therapeutics, Inc. Common Stock position peaked at $2.15M in Q4 2024.
1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Arrowstreet Capital's 13F filing for Q1 2025, filed 14 May 2025.